Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL2418 study of inotuzumab ozogamicin for MRD-positive B-cell acute lymphoblastic leukemia before stem cell transplantation
2023-510516-39-00Phase 2Authorised
- Sponsor
- GIMEMA
- Start
- Oct 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL), sponsored by GIMEMA. Primary endpoint: MRD negativity after treatment. Planned start Oct 2019; status: authorised.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2023-510516-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510516-39-00.